[EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) [FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE (MAGL)
HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)
申请人:F. Hoffmann-La Roche AG
公开号:EP3953360A1
公开(公告)日:2022-02-16
[EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA MONOACYLGLYCÉROL LIPASE (MAGL)
申请人:HOFFMANN LA ROCHE
公开号:WO2020207941A1
公开(公告)日:2020-10-15
The application relates to heterocyclic compounds of the general formula (I), compositions comprising such compounds, a process for preparing these compounds and their medical use. The compounds act as monoacylglycerol lipase (MAGL) inhibitors and are useful in the treatment of neuroinflammation, neurodegenerative diseases, pain, cancer or mental disorders.